KURA ONCOLOGY DL-,0001 WKN: A143UH ISIN: US50127T1097 Kürzel: KUR Forum: Aktien Thema: Hauptdiskussion

Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma https://www.gurufocus.com/news/1468895/kura-oncology-announces-clinical-collaboration-to-evaluate-tipifarnib-in-combination-with-alpelisib-in-head-and-neck-squamous-cell-carcinoma

Kura Oncology Reports Second Quarter 2021 Financial Results https://www.globenewswire.com/news-release/2021/08/05/2276004/35186/en/Kura-Oncology-Reports-Second-Quarter-2021-Financial-Results.html – First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 – – Clinical collaboration with Novartis to evaluate tipifarnib in combination with the PI3Kα inhibitor alpelisib in HNSCC – – KO-2806 nominated as lead development candidate in next-generation farnesyl transferase inhibitor program – – $567.5 million in cash, cash equivalents and investments provide runway into 2024 – ...

$KURA Announces Financing Transactions with $BMY and Hercules Capital, Providing Access to up to $150M. $25M equity investment from $BMY at $18.25/share

So machen Kapitalerhöhungen Spass... https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-announces-oversubscribed-150-million-private

🎈

Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology https://www.globenewswire.com/news-release/2021/03/22/2197210/0/en/Kura-Oncology-Announces-Publication-of-Tipifarnib-Phase-2-Data-in-Journal-of-Clinical-Oncology.html – Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC – – Statistically significant improvement in median PFS compared with median PFS of 3.6 months on last prior therapy (p=0.0012) – – Safety profile consistent with previously published data for tipifarnib – – Results support continuation of AIM-HN registration-directed trial in HRAS mutant HNSCC – ...

Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results https://www.globenewswire.com/news-release/2021/02/24/2181292/0/en/Kura-Oncology-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html -  Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations – – KO-539 continues to demonstrate a wide therapeutic window in dose escalation; protocol amendment to include genetically enriched Phase 1 expansion cohorts – – Tipifarnib receives Breakthrough Therapy Designation from FDA – – $633.3 million in cash, cash equivalents and investments provide runway into 2024 – Management to host webcast and conference call today at 8:00 a.m. ET –    ....

Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma http://www.globenewswire.com/news-release/2021/02/24/2181242/0/en/Kura-Oncology-Receives-FDA-Breakthrough-Therapy-Designation-for-Tipifarnib-in-Head-and-Neck-Squamous-Cell-Carcinoma.html ...today announced that its investigational drug, tipifarnib, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma (HNSCC) with variant allele frequency ≥ 20% after disease progression on platinum-based chemotherapy. Tipifarnib is currently being evaluated in an ongoing registration-directed clinical trial (AIM-HN) in this indication of high unmet need.  ...

Kura teams up with Illumina for a companion diagnostic for lead therapy https://seekingalpha.com/news/3650072-kura-teams-up-illumina-for-companion-diagnostic-for-lead-therapy In a regulatory filing, Kura Oncology (NASDAQ:KURA) announces that on January 04, it entered into a collaboration agreement, with Illumina (NASDAQ:ILMN) for a companion diagnostic test for use with the company’s lead product candidate, tipifarnib. The agreement tided to a project schedule will require Illumina to develop and commercialize an assay as a companion diagnostic test for use with tipifarnib to identify head and neck squamous cell carcinoma (‘HNSCC”) patients with an HRAS mutation. The collaboration covers the United States, the United Kingdom, major European markets, and other countries as mutually agreed by the two parties. Currently, Kura is advancing a global, multi-center, open-label, non-comparative registration-directed clinical trial of tipifarnib in HRAS mutant HNSCC.

Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares https://www.globenewswire.com/news-release/2020/12/11/2144046/0/en/Kura-Oncology-Announces-Closing-of-Public-Offering-and-Full-Exercise-of-Option-to-Purchase-Additional-Shares.html

https://seekingalpha.com/article/4394095-kura-oncology-advanced-precision-medicine-opportunity-excites-not-without-risks

Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock https://www.globenewswire.com/news-release/2020/12/09/2141845/0/en/Kura-Oncology-Announces-Pricing-of-300-Million-Public-Offering-of-Common-Stock.html ...at a price to the public of $37.00 per share. 

Kura Oncology Announces Commencement of Public Offering of Common Stock https://www.globenewswire.com/news-release/2020/12/07/2140893/0/en/Kura-Oncology-Announces-Commencement-of-Public-Offering-of-Common-Stock.html

https://seekingalpha.com/news/3642222-kura-oncology-sized-up-favorably-for-long-term-after-ash-presentation

https://seekingalpha.com/news/3642092-kura-oncology-jumps-16-after-announcing-first-in-human-data-for-aml-candidate Kura Oncology Jumps 16% After Announcing First In-Human Data for AML Candidate